Predicting the outcome for patients with myelofibrosis undergoing an allogeneic hemopoietic stem cell transplant

Blood Cancer J. 2022 Jul 26;12(7):111. doi: 10.1038/s41408-022-00701-w.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Primary Myelofibrosis* / diagnosis
  • Primary Myelofibrosis* / etiology
  • Primary Myelofibrosis* / therapy
  • Transplantation Conditioning
  • Transplantation, Homologous
  • Treatment Outcome